back to Australia directory
australia clinical guidance

Daridorexant for chronic insomnia: regulatory status boundary

A regulator-led status overview based on current TGA and PBS records for daridorexant and chronic insomnia.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

A live TGA ARTG search found no active daridorexant entry on 20 August 2026, so no Australian registered indication or TGA-approved product information was identified. This page is not a prescribing guide: it covers status verification, the current Australian adult-insomnia pathway and the legal framework for exceptional access to an unapproved therapeutic good.
sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

The Bottom Line

  • none is an Australian regulatory approval or PBS recommendation.
  • Search the live ARTG by active ingredient and product name at the point of decision. The negative result recorded on 20 August 2026 is time-limited and must be rechecked before describing daridorexant as unapproved or approved.
  • When no ARTG entry exists, the TGA classifies the product as unapproved, meaning it has not assessed that supplied product for Australian safety, quality or effectiveness.
  • Use the 2026 Australian joint adult-insomnia position statement for diagnosis and first-line care and consider clinically appropriate ARTG-listed options before any exceptional unapproved-product request.
  • Access to an unapproved product requires an eligible Australian practitioner and the applicable Special Access Scheme or Authorised Prescriber pathway, plus state or territory and institutional obligations; TGA does not supply the product.
sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

Practical clinical workflow

1
Confirm chronic insomnia and daytime impairment, evaluate other sleep, mental-health, medical, substance and medicine causes and offer Australian first-line behavioural care before focusing on one overseas medicine.
2
Repeat the live ARTG search and retain the product name, active ingredient, result and date; if an entry appears, retrieve its exact Australian product information and reassess this page before use.
3
If no entry exists and an exceptional need remains, confirm that clinically appropriate registered treatments have been considered and obtain specialist and pharmacy advice about evidence, supply and state or territory law.
4
Use the correct TGA SAS or Authorised Prescriber process, meet practitioner eligibility and consent obligations and explain that access authorization is not equivalent to ARTG registration or a national recommendation.
5
Create a patient-specific monitoring, driving, adverse-event and stopping plan from legally supplied product documentation and specialist advice; do not improvise it from this regulatory summary.
sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

Safety boundaries and escalation

  • Do not prescribe, dispense or advise importation from an overseas label alone; product identity, lawful supply, quality, interactions and patient-specific risks require formal Australian review.
  • Next-day impairment, falls, other sedatives, alcohol, respiratory disease, pregnancy, organ impairment and safety-critical work must be assessed under specialist advice and the supplied product information if lawful access is approved.
  • Report suspected adverse events and product problems through the applicable TGA process and stop or urgently assess severe sedation, altered consciousness, respiratory compromise or complex sleep behaviour.
sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

Implementation

On 20 August 2026 no daridorexant ARTG entry or Australian approved product information was identified; that negative audit is not permanent and must be repeated. TGA access authorization, ARTG registration, PBS subsidy, state or territory medicines law and local formulary approval are separate decisions.
sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:Australian adult insomnia statementTGA daridorexant ARTG searchTGA unapproved-goods access

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australasian Sleep Association, Sleep Health Foundation, Royal Australian College of General Practitioners, Australian Psychological Society, Pharmaceutical Society of Australia and Australian Primary Health Care Nurses AssociationManagement of adult insomnia in Australia: A joint position statementDOI 10.1093/sleepadvances/zpag086 路 Sleep Advances, published online 2026; listed by the Australasian Sleep Association as current Australian guidance 路 accessed 2026-08-20
    view source
  2. Therapeutic Goods AdministrationAustralian Register of Therapeutic Goods search for daridorexantNo active daridorexant entry identified in the live ARTG search on 20 August 2026; recheck before any clinical use 路 accessed 2026-08-20
    view source
  3. Therapeutic Goods AdministrationAccess an unapproved therapeutic good (health practitioners)Regulatory guidance updated 28 July 2026 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.